SAN FRANCISCO--(BUSINESS WIRE)--Glytec, a clinical information technology company solely dedicated to the mission of improving insulin management and glycemic control, today announced that several abstracts featuring the company’s eGlycemic Management System™ (eGMS™) have been selected as poster presentations at the American Diabetes Association (ADA) 74th Scientific Sessions. The 74th Scientific Sessions, taking place from June 13th to June 17th in San Francisco, are the premier venue for exchanging news and showcasing innovation to the diabetes community.
During the conference, several posters will be presented that highlight the success of improved glycemic management achieved by healthcare providers utilizing Glytec’s eGMS. The Glytec system’s treatment algorithms are designed to keep hospital patients from hyperglycemic or hypoglycemic states after insulin treatment is ordered by the physician.
The following presentations will take place at the ADA 74th Scientific Sessions:
- Friday, June 13: Guillermo Umpierrez, MD, professor of medicine in the division of endocrinology and metabolism at Emory University, will deliver two presentations. The topic of the first presentation is Inpatient Diabetes Management and the second is titled, “Randomized, Controlled Trial of Intensive vs. Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery.”
- Saturday, June 14: Carlos Mendez, MD, director of the diabetes management center, at Albany VA Medical Center will present “Daily Inpatient Glycemic Survey (DINGS): Report of a Process to Identify and Assist in the Management of Hospitalized Patients with Diabetes or Hyperglycemia” during the General Poster Sessions.
- Sunday, June 15: Posters titled, “Mountain States Health Alliance Achieves Dramatic Improvements in Glycemic Control with the Comprehensive Insulin-Dosing Software Platform by Glytec” by Andrew Rhinehart, MD, medical director of Mountain States Health Alliance and “Hospitalization Costs, Resource Utilization, and Clinical Outcome in General Surgery Patients with Hyperglycemia and Diabetes” by Dawn Smiley, MD, investigator at Emory University School of Medicine will be exhibited. Additionally, a related presentation by Dr. Smiley, “Hospitalization Costs, Resource Utilization, and Clinical Outcome in Patients Undergoing CABG Receiving Intensive vs. Conservative Glucose Control” will take place during the Late Breaking Poster Session.
“Glytec’s eGMS is an example of how advanced clinical information technology is currently being employed to improve healthcare, from both the patient and the operational perspectives,” says Laurel Fuqua, RN, Chief Clinical Innovation Officer at Glytec. “The sessions and exhibits at this year’s ADA Scientific Sessions can help healthcare providers become more familiar with leading-edge research, products and services that offer the promise of helping to alleviate pressures they now face in terms of patient care, staffing and cost containment. There are several presentations at this year’s ADA meeting showcasing the importance of inpatient glycemic management in improving the health status of people with diabetes who are hospitalized. We are excited that Glytec had many abstracts, posters and presentations accepted. And we’re proud of how they highlight research results using our inpatient system,” says Fuqua.
Glytec is a clinical information technology company founded in 2006. It is the only company to receive FDA clearance for computerized intravenous, subcutaneous and pediatric insulin dosing algorithms: Glucommander IV™ (2006), Glucommander SubQ™ (2010) and Glucommander Pediatrics™ (2012). The Glucommander™ suite is cloud-based and augmented by Glytec’s GlucoMetrics™ and GlucoSurveillance™ analytics. Glytec’s eGlycemic Management System™ enables hospitals to significantly reduce the frequency, risks and costs of hyperglycemia and hypoglycemia and offer unprecedented quality to their diabetic and surgical patients. For more information, please visit: http://www.glytecsystems.com/